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warning extended to conventional antipsychotics). A 2011 AHRQ comparative ef-
fectiveness review supports efficacy of certain antipsychotics for dementia and
anxiety disorder, but prescribing of drugs without supporting evidence continues
in practice. For example, while aripiprazol, olanzapine and risperidone were found
to have small but significant benefits for dementia symptoms, this analysis showed
quetiapine was most prescribed in this population; haloperidol was prescribed
more than twice as often as aripiprazole. CONCLUSIONS: In spite of the clinical
findings, this analysis found growing use of antipsychotic medications in the el-
derly population and prescribing of specific drugs in the absence of supporting
evidence.
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OBJECTIVES: Korea’s Health Insurance Review and Assessment Service (HIRA) has
been in charge of updating economic evaluation (EE) guideline. The purpose of this
study is to provideminimum standards for submissions, thus increase the compa-
rability between submissions and help decision makers to reach consistent reim-
bursement decisions. METHODS: To prioritize the topics of EE guideline revision,
HIRA has reviewed foreign EE guidelines focusing on currently updated topics, and
evaluated practical and theoretical needs for updating those topics. Gaps between
current recommendations and domestic practice patterns were assessed by eval-
uating dossiers submitted to HIRA for reimbursement decision. In addition, survey
results from pharmaceutical companies as well as decision makers regarding cur-
rent guideline were considered. In developing current revision, experts meetings
were held 6 times, and working group meetings with pharmaceutical companies
were held 4 times to reach as much consensus as possible. RESULTS: Current EE
recommendations are in line with most of foreign EE guidelines, yet the gap be-
tween current recommendations and domestic reality emerged due to lack of high
quality domestic data. Some vague expressions have been noted. To reduce con-
fusion,we clarified the level of data requirement (must, should, preferred) based on
data availability and strength of the evidence. We stipulate QALY measurement,
modeling methods, sensitivity analysis, and perspective in this revision. Minor
updates were also included. CONCLUSIONS: Current revision strives to reduce
comparability and consequently, enhance comparability among submissions by
providing concrete recommendations.
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OBJECTIVES: To evaluate three different methods to compute risk-adjusted phar-
macy performance scores based on adherence-based pharmacy quality indicators.
METHODS: This retrospective cohort study used the 2007 Mississippi Medicare
administrative claims dataset. Patient medication adherence was assessed using
the proportion of days covered (PDC) measures proposed by the Pharmacy Quality
Alliance for seven therapeutic classes of medications. Pharmacy performance
scores were computed for all pharmacies serving Medicare beneficiaries in the
state. Risk-adjusted pharmacy performance scores were computed using a classi-
cal logistic regression model (Method 1), a hierarchical random effects model
(Method 2) and the shrinkage estimators of the random-effects model (Method 3).
Patient demographics, income subsidy status, and co-morbidity burden were used
as variables for risk adjustment. The agreement in classification of pharmacies
based on unadjusted and adjusted scores was measured using Cohen’s kappa
coefficient. RESULTS: The logistic regressionmodel and the random-effects model
displayed good predictive ability (c-statistic0.7) for all therapeutic classes. The
residual intraclass correlation coefficient ranged from 0.008 to 0.012 indicating that
although pharmacy-level factors may have a significant impact, they are not as
important as patient-level factors in determining adherence. Higher levels of
agreement were observed between pharmacy classifications based on unadjusted
scores and risk-adjusted scores obtained from Methods 1 and 2 (0.5kappa0.74)
with the percentage change in classification ranging from 16.3%-28.4%. Scores
based on Method 3 produced fewer outliers and showed minimal agreement with
unadjusted scores (0.19kappa0.35). When compared to risk-adjusted scores,
unadjusted scores classified 8-12% of the low performing pharmacies as high per-
forming and classified 20-30% of the pharmacies in the top 20% as low performers.
CONCLUSIONS: Risk-adjusted scores produced more robust indicators of phar-
macy quality than unadjusted scores. Not adequately addressing the effects of
patient case-mix while measuring quality could have severe implications if these
measures are used for pay for performance programs or generating quality report
cards.
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OBJECTIVES: Serumpotassium levels should be assessed periodically following the
initiation of spironolactone treatment. This study examined the rate of laboratory
follow-up and factors affecting it at an academic medical center.METHODS: Adult
patients starting spironolactone treatment between January 1, 2008 and September
30, 2010 were studied. Subjects were excluded if the indicated disease was not
followed up at the medical center, or the exact date of the first spironolactone
prescription was unknown. Data were collected by computer query and chart re-
view. Survival analysis examined the factors predicting the time to first serum
potassium testing after spironolactone initiation. RESULTS: A total of 161 patients
were included (mean age 51.1 years, 57% female), 29% of whom had some renal
impairment (creatinine clearance 60 ml/min). Spironolactone was most com-
monly used for ascites/edema due to primary liver disease (45.3%), followed by
congestive heart failure (19.3%) and polycystic ovary syndrome or other hormone-
related disorders (18.6%). Themedian time to first potassium testwas 22 days. After
adjusting for age, gender, renal function and insurance status, medical indication
was the only factor impacting time to first potassium check-up. Compared to pa-
tients with primary liver disease, patients who used spironolactone for ascites/
edema not due to hepatic or cardiac causes (e.g., non-hepatic malignancy, ne-
phrotic syndrome) were likely to have a potassium level checked earlier (hazard
ratio [HR]2.2, 95% CI1.04-4.6), whereas potassium testing was more likely to be
delayed in patients with hormone-related disorders (HR0.4, 95% CI0.2-0.9) or
hypertension (HR0.4, 95% CI0.2-0.8). CONCLUSIONS: Medical indication was
significantly predictive of the time to first potassium check in patients receiving
spironolactone. It is surprising that renal dysfunction was not a factor, while the
association with indication has many possible explanations from increased rou-
tine lab testing for some indications and higher risks of hyperkalemia complica-
tions. Further studies are needed to validate and understand these data.
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OBJECTIVES:Medical errors cause approximately 44,000 to 98,000 injuries annually
in the United States (US). This study estimated the occurrence of medical errors
and associated costs using actuarial methodology developed by Milliman, Inc. ap-
plied to Premier hospital data. METHODS: The Milliman study utilized an expert
panel to estimate how often medical injuries were likely to be associated with a
medical error rather than the underlying disease. Injuries were classified into five
groups based on the likelihood that they were associated with amedical error. The
midpoint of each range of likelihood of medical error was applied to the frequency
of each medical injury to establish the rate of medical error. This study utilized
Milliman’s ranges and midpoints applied to Premier data. Injury rates, error esti-
mates and cost-per-error estimates were developed from Premier 2008-2009 data.
A visit qualified as an injury visit if1 of 97 injury groupings identified byMilliman
occurred. Non-injury control groups were established using propensity score
matching. Population estimates were projected from Premier to all US acute care
hospitals. RESULTS: While the focus of the earlier report was health plan claims
data, this study utilized hospital billing records to demonstrate direct cost of med-
ical errors to hospitals. The rates of medical errors were similar to the Milliman
study and both studies found pressure ulcers and postoperative infection were the
most common types ofmedical errors.Milliman estimated the total cost ofmedical
errors to be approximately $17 billion in 2008. This analysis found that hospitals
bear approximately 1 billion in costs related to medical errors. CONCLUSIONS:
Utilizing methods developed by Milliman, this study estimated the rates and cost
of medical errors to hospitals utilizing hospital billing data, revealing similar pat-
terns of errors.
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OBJECTIVES: Prescription drug monitoring programs (PDMPs) are viewed as a tool
to reduce abuse and diversion of prescription controlled substances (CS), although
little is known about their effectiveness in achieving these goals. The purpose of
this project was to assess the impact of the Kentucky All Schedule Prescription
Electronic Reporting program (KASPER) on pharmacists’ dispensing behavior and
to evaluate its perceived effectiveness in reducing drug abuse, diversion, and doc-
tor shopping. METHODS: Surveys were mailed to 2,018 pharmacists in Kentucky.
After two weeks, a reminder postcard and second survey were sent to non-re-
sponders. Responseswere coded and descriptive analysiswas conducted in STATA
11. RESULTS: Responses were received from 575 pharmacists (response rate 
28.5%). The majority (77%) indicated they had requested a patient’s CS history
through KASPER. For those who had not utilized KASPER, the primary reason was
lack of Internet access at the practice-site. When asked if their CS dispensing has
changed since KASPER implementation, 67% indicated no change while 13% indi-
cated a decrease in dispensing and 15% indicated an increase. For those reporting
a decrease, reasons cited include implementation of KASPER (36%), increased law
enforcement activity (15%) and media coverage of drug abuse and diversion (8%).
Themajority (83%) of respondents believe that KASPER is an effective tool to reduce
drug abuse and diversion and 79% feel it is an effective tool to reduce doctor
shopping. CONCLUSIONS: Internet access was the primary reason for not using
KASPER. Most pharmacists have not perceived a change in CS dispensing since
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